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Dry eye disease is an ocular condition that affects millions of people in the United 
States alone, especially the elderly population. Current treatment methods for mild cases 
of the disease are saline-, polymer-, or hyaluronic acid (HA)-based eye drops. Recent 
findings show that HA-based eye drops are more effective. In addition, HA is known to 
act as a natural lubricant. However, one of the major problems with current eye drop 
technology is that they need to be reapplied frequently due to blinking of the eye. Thus, 
an HA binding eye drop technology that prolongs HA retention on the ocular surface 
would benefit people who experience dry eye symptoms and therefore need an effective 
treatment method for smooth blinking with sufficient hydration. Recently, a biofunctional 
polymer-peptide system was reported that enhanced HA retention on ocular surfaces. 
This system has one peptide that binds to HA and another peptide that binds to the ocular 
surface via transmembrane mucins. Here, we investigate a multivalent polymer-peptide 
system that further enhances HA retention due to multivalent peptides. We harnessed a 
system that comprises of an inclusion complex (IC) of alpha-cyclodextrin/poly(ethylene 
glycol) or PEG. α-CD is a 6-membered ring shaped oligosaccharides with a molecular 
cavity and has several hydroxyl groups available for further chemical modifications. 
Since, α-CD can thread on PEG chains, the IC provides multi-valency through hydroxyl 
groups of α-CD for multi-peptide attachment. This multivalent approach allows HA to be 
immobilized on the ocular surface, thus allowing for longer retention time due to an 
overall higher binding affinity. We synthesized PEG/CD IC and end-capped PEG chains. 
We further modified hydroxyl groups of α-CD into carboxylic acids to enhance its 
aqueous solubility. The carboxylic acid groups were further modified to acrylate 
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functionality. The thiol-containing mucins- and HA-binding peptides were linked to the 
PEG/CD complex via thiol-acrylate Michael-addition reaction. We applied the resultant 
multivalent polymer-peptide system with HA on ex vivo rabbit eyes and studied HA 
retention overtime. We also compared the HA retention with a 2-arm and an 8-arm 
polymer-peptide system. Through ex vivo rabbit studies, this novel eye-drop technology 
of a multivalent polymer-peptide system retains ~1.2 times more HA than the 8-arm 
polymer-peptide system, ~1.3 times more HA than the PEG/CD complex without HA 
binding peptide, and ~1.5 times more HA than a commercially available HA-based eye 
drop. Through our preliminary in vivo mouse studies, this new eye drop technology 
showed an ocular surface residence time of ≤ 30 minutes as compared to ≤ 15 minutes for 
the 2-arm and 8-arm polymer-peptide systems and for a commercially-available HA-
based eye drop. Thus, we anticipate that a multivalent HA-binding eye drop technology 
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1.1 The ocular surface and dry eye disease 
The ocular surface is the front-most outer surface of the human eye, separating the 
eye from the environment. It is made up of the cornea, conjunctiva, and the tear film, and 
is shown in Figure 1. Its main function is to protect the eye from injury and infection. 
The cornea is a clear tissue that acts as the eye’s outermost lens by controlling and 
focusing light into the eyes. The conjunctiva is a thin, transparent, mucous layer that 
covers the front of the sclera (or the white part of the eyes) and lines the insides of the 
eyelids.1 The tear film covers the cornea and is the eye’s first defense to the environment. 
Figure 1 also shows the three layers of the tear film: the mucin layer, the aqueous layer, 
and the lipid layer (from the innermost to the outermost layer). The mucin layer coats the 
cornea and acts as an anchor, holding the tear film to the eye. The aqueous layer is the 
watery layer that makes up the majority of our tears. The lipid layer helps keep tears from 
spilling out of the eyes or evaporating from the surface of the eyes.2,3,4 
 
FIGURE 1. Diagram of the ocular surface components and the tear film layers. 
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Dry eye is an ocular condition prevalent in the elderly population, but affects 
thousands of people on a day-to-day basis. Although dry eye is a multifactorial disease, it 
occurs mostly due to any alterations in the tear film composition and stability with 
potential damage to the ocular surface. There are two types of dry eye: aqueous-deficient 
and evaporative. Aqueous-deficient dry eye is caused by the tear film’s inability to 
produce sufficient tear fluid, whereas evaporative dry eye is caused by increased tear 
evaporation rate because of damage to the lipid layer in the tear film.5 Symptoms include 
dryness or lack of hydration, discomfort, and visual disturbances and pain in the eye. 
About 40% of Americans have reporting experiencing dry eye symptoms.6 There have 
been many different approaches to treating dry eye symptoms, most involving the 
application of a saline or polymer-based eye drop to reduce discomfort and increase 
water retention on the ocular surface. About 1 out of 5 adults report using over-the-
counter eye drops to treat symptoms at least five times per week. However, 63% of 
people who use over-the-counter eye drops report that these drops are not sufficiently 
effective to reduce the symptoms.6 It is mostly due to the temporary nature of the 
treatment, and these artificial tears must be reapplied frequently because of their short 
residence time on the eye. 
 
1.2 Current treatment method 
Currently, the main treatment method for mild cases of dry eye symptoms is 
application of eye drops. Throughout the history of eye drops, there have been mainly 
three generations of eye-drop compositions. The first generation of modern artificial tears 
can be traced back to the product, Collyrium, which means “eye wash” in Latin. This 
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product and other early attempts at dry eye relief gave rise to saline-based eye drops; 
however, these artificial tears spread poorly across the ocular surface and had short 
retention time leading to transient relief. Around the 1980s, artificial tears advanced to 
integrating natural and synthetic polymers (e.g., methylcellulose derivatives, 
poly(ethylene glycol), and polyvinyl alcohol) in eye drops. The second generation, 
polymer-based eye drops offered better retention time due to the structure of polymers. 
These polymers have high viscosity, which allowed them to stay on the eye longer than 
the preceding saline-based eye drops. This demonstrates a clear structure-property 
relationship for the use of polymers in eye drops. However, one of their major drawbacks 
is its occasional, transient visual blurring due to their gel-forming nature.7 The third 
generation of modern artificial tears incorporates HA (Figure 2, chemical structure of 
HA), which is a naturally occurring polysaccharide, or more specifically an anionic 
glycosaminoglycan that is a major component of the extracellular matrix. It is a long 
polymeric chain with many carboxylic acid and hydroxyl functional groups. Its long 
chain highlights its elastic properties as a viscoelastic molecule, allowing it to bind 
together for long-lasting coverage. The carboxylic acid and hydroxyl functional groups 
allow it to form many hydrogen bonds, causing it to be extremely hydrophilic and 
allowing it to prolong water retention.8 HA has been shown to ameliorate dry eye 
symptoms due to its viscoelastic nature, leading to its ability to prolong water retention, 
tear film stability, and surface lubrication,9 as well as reduce tear evaporation and permit 
uninterrupted blinking.10 In addition, HA has a number of desirable therapeutic 
properties, for example, it encourages corneal wound healing by promoting epithelial cell 
migration11 and reduces inflammation.12 Recent studies further indicate that anionic 
��
polysaccharide moieties, including HA, can enhance the spreading of the tear film lipid 
layer, which is an added clinical benefit of HA for ocular application.13 It has also been 
demonstrated that HA can be beneficial for patients with both aqueous deficient and 
evaporative dry eye because it increases tear volume and tear film stability.14 In the 
market today, there are commercially available eye drops containing 0.1-0.2% HA, such 
as Opticalm, Scope, Oxyal, and Hylo. Even though this third generation HA-based eye 
drop effectively wets and lubricates the ocular surface, it still has a low residence time 
overall of about <10 min, which requires frequent application.15 
 
FIGURE 2. Chemical structure of HA. 
Compared to the other eye drops, 0.2% HA has a longer mean half-life in artificial 
tears solutions of 321 seconds on the ocular surface, as compared to 0.3% hydroxyl 
propyl methylcellulose’s (HPMC) half-life of 44 seconds and 39 seconds of 1.4% 
poly(vinyl alcohol) (PVA).16 HA concentrations of 0.1% and 0.3% have been shown to 
delay tear break up time (TBUT), an important parameter that reflects tear film stability. 
Compared to the polymer-based eye drops containing HPMC or PVA, 0.1% HA has been 
shown to be superior in stabilizing the pre-corneal tear film.17 HA is also superior to 
HPMC and PVA for water retention and protection of human corneal epithelial cells from 
dehydration.18 The major limitation for current eye drop technology is its low retention 
time on the ocular surface. Thus, an eye drop technology that effectively binds HA to the 
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ocular surface is needed to enhance its retention time, which potentially can eliminate the 
necessity of frequent eye-drop instillation. 
 
1.3 Multivalent polymer-peptide system 
Our overall objective is to enhance the binding of HA to the ocular surface. This 
would help retain a thin film of moisture on the ocular surface to mimic the smooth, 
hydrated, and lubricated natural surface. As mentioned previously, the mucin layer of the 
tear film acts as an anchor, holding the tear film to the eye. Thus, theoretically, binding 
HA to a component of the mucin layer would allow for the optimal and longest retention. 
Mucins are high-molecular weight glycoproteins with a protein backbone and high 
carbohydrate content. There are two types of mucins in the tear film: membrane-bound 
and secreted. The membrane-bound mucins are embedded in the lipid bilayer of the 
mucin layer, while the secreted mucins are released into the extracellular environment of 
the aqueous layer.19 Membrane-bound mucins such as mucin-1, mucin-16, and mucin-20 
contain sialic acid in the O-glycosylated extracellular domains.20 Sialic acid is a family of 
acidic monosaccharides, and it is usually found at the outermost of the glycan chains on 
the cell surface proteins and lipids.21 Therefore, given the location of sialic acid on the 
membrane-bound mucins in the mucin layer of the tear film, there will be easier access to 
sialic acid, allowing sialic acid to be harnessed as the potential anchoring site for 
immobilizing HA on the ocular surface. Current research shows that a certain sialic acid 
binding peptide (or SABpep) binds to sialic acid well, with a strong binding affinity22; 
therefore, SABpep (GGSPYGRC) was chosen as the mucin anchoring peptide and 
HABpep (STMMSRSHKTRSHHVGC) to bind HA.22 
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Polyethylene glycol (PEG) was chosen as the space-polymer because of its 
properties that make it especially useful in various biological, chemical and 
pharmaceutical settings. PEG is the current ideal polymer to conjugate with proteins due 
to its non-toxic and non-immunogenic, hydrophilic/aqueous/soluble, and highly flexible 
properties. It can be added to media or conjugated to molecules without interfering with 
cellular functions or target immunogenicities. When attached to proteins, it decreases 
protein aggregation and increases solubility. Since it is a linear chain, its highly flexible 
nature provides for bioconjugation without steric hindrance.23 Figure 3 shows the 
structure of PEG, which has hydroxyl groups at the two ends of the long chain molecule, 
allowing it to form hydrogen bonds, and thus making it hydrophilic. This particular 
characteristic of its structure allows it to increase the solubility of anything that it is 
conjugated to. This demonstrates the structure-property relationship of PEG. 
 
FIGURE 3. Chemical structure of PEG. 
 
PEG can be complexed with alpha‐cyclodextrin (α‐CD), using supramolecular 
chemistry, to create an inclusion complex (IC) of PEG/CD. α‐CD is a sex-member 
oligosaccharide with the structure of a doughnut ring with an inner cavity and an outer 
ring.24 It contains many hydroxyl groups that can be easily modified to create a diverse 
amount of functions through different chemical reactions. Succinyl-α‐CD (succ-CD) has 
a carboxylic acid functional group instead of one of the hydroxyl groups of α‐CD, which 
provides a site for conjugation to attach a binding peptide that attaches HA (HA-binding 
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peptide or HABpep) or modified to attach SABpep that binds to sialic acid in the mucin 
layer. The succ-CD rings physically thread onto the PEG chains, and this allows it to 
resemble a molecular necklace. The succ-CD rings are incredibly mobile, and thus, can 
slide along and rotate around the PEG chain.24 Figure 4 shows the structure of succinyl-
α‐CD. The amino acid sequence of SABpep is GGSPYGRC. The amino acid sequence of 
HABpep is STMMSRSHKTRSHHVGC. Both peptides contain thiols (SH) that undergo 
thiol-Michael addiction reactions with enes (such as acrylate). Therefore, the PEG/CD IC 
with –COOH functional groups can be modified to acrylate functional groups, which can 





FIGURE 4. Chemical structure of succinyl-α-cyclodextrin. 
 
 




















































2. MATERIALS AND METHODS 
2.1 Materials 
Succinyl-α-cyclodextrin (Succ-CD) (Mw 1300 Da) was purchased from 
Cyclodextrin-Shop (Tilburg, Netherlands). Azide-PEG-Azide (Mw 20 KDa) was 
purchased from Creative PEGWorks (Chapel Hill, NC). And DBCO-PEG4-Hydroxyl 
(Mw 508.61 Da) was purchased from Click Chemistry Tools (Scottsdale, AZ). 
Triethylamine (TEA) (Mw 101.2 Da) was purchased from Chem-Impex (Wood Dale, IL). 
Acryloyl chloride (Mw 90.51 Da) was purchased from Sigma-Aldrich (St. Louis, MO). 
Immobilized TCEP Disulfide Reducing Resin (or TCEP gel) (Mw 286.65 Da, 
concentration of 8 µmol/mL) was purchased from ThermoFisher Scientific (Rockford, 
IL). The sialic acid binding peptide (SABpep or GGSPYGRC) (Mw 795.86) and the 
hyaluronic acid binding peptide (HABpep or STMMSRSHKTRSHHVGC) (Mw 1942.21 
Da) were custom synthesized and purchased from Synpeptide (Shanghai, China). 
 
2.2 Synthesis of End-capped PEG/Succ-CD 
Succ-CD (1 g, 0.769 mmol) was dissolved in 3 mL of distilled water. Azide-PEG-
Azide in a 0.05 molar ratio relative to Succ-CD (50 mg, 2.5 µmol) was dissolved in 0.4 
mL of distilled water. Then, the Succ-CD solution was added to the PEG solution, 
vortexed, and stirred overnight at room temperature. For the PEG end-capping reaction, 
DBCO-PEG4-Hydroxyl in a 4 molar ratio (2.54 mg, 5 mmol) was dissolved in 0.2 mL of 
anhydrous dimethyl sulfoxide (DMSO). This solution was then added to the PEG/Succ-
CD inclusion complex, vortexed, and stirred overnight at room temperature. Then, it was 
dialyzed against distilled water overnight (Mw cutoff 3500 Da). Water was then removed 
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by lyophilization to produce end-capped PEG/Succ-CD, which was characterized by 1H-
NMR in DMSO (Figure 5A) using the Bruker Advance III 500 MHz NMR spectrometer. 
The Bruker TopSpin software was used to process the NMR spectrum. 
 
2.3 Synthesis of PEG/Succ-CD/Acrylate 
PEG/Succ-CD (125 mg, 0.096 mmol of Succ-CD) was dissolved in 3 mL of 
anhydrous dimethylformamide (DMF) and kept stirring on a stir plate. TEA was added 
dropwise while stirring in a 15 molar ratio to Succ-CD (201.19 µL, 1.44 µmol). Then, 
acryloyl chloride was added dropwise while stirring in a 15 molar ratio to PEG/Succ-CD 
(116.56 uL, 1.44 µmol). This mixture was left stirring overnight at room temperature, and 
then precipitated in chloroform and rotovaporized to remove TEA salt and DMF. Then, it 
was dialyzed against distilled water overnight (Mw cutoff 500-1000 Da) and lyophilized 
to produce PEG/Succ-CD/Acrylate, which was characterized by 1H NMR in D2O 
(Figure 5B). 
 
2.4 Synthesis of PEG/Succ-CD/SABpep and PEG/Succ-CD/SABpep/HABpep and 8-
arm PEG/SABpep/HABpep 
SABpep and HABpep were characterized by 1H NMR in D2O (Figure 5C and 
5D, respectively). To synthesize PEG/Succ-CD/SABpep, PEG/Succ-CD/Acrylate (15 mg, 
0.0115 mmol of Succ-CD) was dissolved in 1 mL of PBS. TCEP gel (1 mL, 8 mmol) was 
washed with PBS 2 times, and SABpep in a 0.5 molar ratio (4.59 mg, 5.77 µmol) was 
dissolved in 1 mL of PBS and added to the TCEP gel and was stirred for an hour. After 
centrifugation to remove the TCEP gel, the reduced peptide was added to the PEG/Succ-
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CD/Acrylate. To synthesize PEG/Succ-CD/SABpep/HABpep, the same protocol was 
used, however with another set of TCEP gel for HABpep. The reagents were: PEG/Succ-
CD/Acrylate (15 mg, 0.0115 mmol of Succ-CD) in 1 mL of PBS, two sets of TCEP gel (1 
mL each, 8 mmol), SABpep in a 0.5 molar ratio (4.59 mg, 5.77 µmol) in 1 mL of PBS, 
and HABpep in a 0.5 molar ratio (11.21 mg, 5.77 µmol) in 1 mL of PBS. Both these 
reactions were stirred overnight at room temperature. Then, they were dialyzed against 
distilled water for 4 hours (Mw cutoff 3500 Da), and lyophilized to produce PEG/Succ-
CD/SABpep and PEG/Succ-CD/SABpep/HABpep, which were characterized by 1H 
NMR in D2O (Figure 5E and 5F, respectively). To synthesize 8-arm 
PEG/SABpep/HABpep, the same protocol was used, however with 8-arm PEG with 
maleimide groups at the end to conjugate with the thiols in SABpep and HABpep.	
 
2.5 Ex vivo testing of PEG/Succ-CD/SABpep and PEG/Succ-CD/SABpep/HABpep 
binding over 3 periods of eye drop application 
Cadaveric rabbit eyes were purchased from Pel-Freez Biologicals (Rogers, AR), 
and the ocular surface/conjunctivas of the eyes were excised. PEG/Succ-CD/SABpep and 
PEG/Succ-CD/SABpep/HABpep solutions, both at 2 mg/mL concentration, were applied 
on the ocular surface of the rabbit eyes for 20 min. After washing twice with PBS, HA-
FL, at 30 ug/mL, was applied to the same area for 20 min. The standard curve HA-FL 
concentrations were 0, 10, 30, 50, 75, 100, and 200 µg/mL. The over-time retention of 
HA on the conjunctiva tissues was examined by using Synergy™ H4 Hybrid Multi-Mode 
Microplate Reader (BioTek, Winooski, VT) to measure fluorescence values with 
endpoint scan starting at time t = 0 (20 min after polymer peptide application and 20 min 
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after HA-FL application), and periodically every 5 min for a total of 75 min. The first 
measurement provided a standard curve of fluorescence values at the above 
concentrations. Then, the tissues were washed with PBS to remove any unbound HA-FL 
before fluorescent reading and then measured again 15 times, with 5 min in between each 
wash. After the 15th wash, the polymer-peptide and HA-FL eye drop solutions were re-
administered for 20 min each and then the 15 washes were repeated for the 2nd period. 
This was then repeated for a 3rd period. The fluorescent values of PEG/Succ-CD/SABpep 
(control) were then compared to the fluorescent values of PEG/Succ-
CD/SABpep/HABpep (sample). All groups were performed in triplicate. This ex vivo 
study is to demonstrate the periodic effectiveness of the eye drop technology. 
 
2.6 In vivo testing of PEG/Succ-CD/SABpep/HABpep binding 
In vivo tests were performed on mice (C57BL/6, Charles river), and they were 
anesthetized with isoflurane (Baxter, IL). Six mice were used for 3 different time points, 
2 mice per time point, and each eye was used for either a control eye drop or sample eye 
drop. Mice 1 and 2 were for 0 min time point, mice 3 and 4 were for 15 min time point, 
and mice 5 and 6 were for 30 min time point. The mice were split into 4 sets to compare 
the eye drop solutions at the 3 different time points t = 0 min, 15 min, and 30 min, as 
shown in Figure 7. The first two sets (Figures 7A and 7B) compare the negative control 
eye drop solution of mice 1, 3, and 5. The third set (Figure 7C) compares the positive 
control eye drop solution of mice 2, 4, and 6. The fourth set (Figure 7D) compares the 
sample eye drop solution of mice 2, 4, and 6. The left eyes of mice 1, 3, and 5 (1L, 3L, 
and 5L) were treated with an eye drop containing the negative control of PBS (total 
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volume 5 µL), and the right eyes of mice 1, 3, and 5 (1R, 3R, and 5R) were treated with 
an eye drop containing the negative control of the multivalent polymer-peptide, SABpep-
PEG/CD-HABpep (without HA-FL) (total volume 5 µL, with a concentration of 2 
mg/mL). The left eyes of mice 2, 4, and 6 (2L, 4L, and 6L) were treated with an eye drop 
containing a combined 1:1 vol ratio of PBS and 1 mg/mL of HA-FL (total volume 5 µL), 
and the right eyes of mice 2, 4, and 6 (2R, 4R, and 6R) were treated with an eye drop 
containing a combined 1:1 vol ratio of 2 mg/mL SABpep-PEG/CD-HABpep and 1 
mg/mL of HA-FL (total volume 5 µL). We used 1 mg/mL HA-FL as it corresponds to 
0.1%, which is used in commercial eye drops. The mice were then sacrificed at the 3 
different time points: mice 1 and 2 were sacrificed at 0 min right after eye drop 
application, and mice 3-6 were allowed to regain consciousness as isoflurane gas was 
removed, and then they were sacrificed at either 15 min or 30 min after eye drop 
application. Whole mice were imaged immediately after sacrificing using a fluorescent 
dissecting microscope (Nikon, Melville, NY), allowing us to take images of the eye 





3.1 NMR Results 
After a multi-step synthesis of SABpep-PEG/Succ-CD-HABpep, NMR was used 
to characterize it to confirm that the actual product synthesized is SABpep-PEG/Succ-
CD-HABpep. Figure 5 depicts the NMR results for PEG/Succ-CD in DMSO (Figure 
5A), PEG/Succ-CD/Acrylate in D2O (Figure 5B), SABpep in D2O (Figure 5C), 
HABpep in D2O (Figure 5D), PEG/Succ-CD-SABpep in D2O (Figure 5E), and 
SABpep-PEG/Succ-CD-HABpep in D2O (Figure 5F). 1H NMR (400 MHz, D2O): δ 3.5-
3.7 (4H, PEG), 4.9-5.1 (6H, succ-CD), 6.7-6.9 (3H, SABpep), and 8.4-8.6 (16H, 
HABpep). 
 In order to identify the ratio of PEG to Succ-CD to SABpep to HABpep to 
determine the valency of the product, the NMR peaks corresponding to the number of 
hydrogens of each were integrated. The 4H in PEG (from -CH2-CH2) at ~3.6 ppm 
corresponds to a signal of 5.1269 units. The 6H in Succ-CD (from –OH) at 5.0 ppm 
corresponds to a signal of 1.7078 units. The 3H in SABpep at 6.8 ppm corresponds to a 
signal of 0.2300. And the 16H in HABpep at 8.5 ppm corresponds to a signal of 0.6784. 
From these integrations, the ratio of each can then be calculated as follows: 
PEG (Mw 20,000 g/mol with repeat unit, n = 44 g/mol; 4H present in signal of 5.1269; x 
= relative number of PEG chains;): 
44 ∗ 𝑛 = 20,000 
∴  𝑛 = 454 𝑟𝑒𝑝𝑒𝑎𝑡 𝑢𝑛𝑖𝑡𝑠 
𝑥 ∗ 454 ∗ 4 =  5.1269 
∴  𝑥 = 0.0028 
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Succ-CD (6H present in signal of 1.7078; y = relative number of Succ-CD): 
𝑀𝑎𝑥𝑖𝑚𝑢𝑚 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑆𝑢𝑐𝑐 − 𝐶𝐷 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒𝑠 𝑜𝑛 𝑒𝑎𝑐ℎ 𝑃𝐸𝐺 𝑐ℎ𝑎𝑖𝑛 =
𝑛
2 =  
454
2 = 227 
𝑦 ∗ 6 =  1.7078 
∴  𝑦 = 0.2846 
SABpep (3H present in signal of 0.2300; z1 = relative number of SABpep): 
𝑧! ∗ 3 =  0.2300 
∴  𝑧! =  0.07667 
HABpep (16H present in signal of 0.6784; z2 = relative number of HABpep): 
𝑧! ∗ 16 =  0.6784 
∴  𝑧! =  0.0424 
Ratio of PEG to Succ-CD to SABpep to HABpep: 
𝑃𝐸𝐺 = 0.00282318 = 1 
𝑆𝑢𝑐𝑐 − 𝐶𝐷 = 0.2846 ≅ 100 
𝑆𝐴𝐵𝑝𝑒𝑝 =  0.07667 ≅ 27  
𝐻𝐴𝐵𝑝𝑒𝑝 =  0.0424 ≅ 15 
𝑇𝑜𝑡𝑎𝑙 𝑣𝑎𝑙𝑒𝑛𝑐𝑦 = 𝑆𝐴𝐵𝑝𝑒𝑝 + 𝐻𝐴𝐵𝑝𝑒𝑝 = 42 
 
Thus, from the NMR results, for every PEG chain, there are approximately 100 
succ-CD molecules threaded on it, with approximately 27 SABpep and 15 HABpep 
attached. This demonstrates that the multivalent SABpep-PEG/Succ-CD-HABpep system 
has approximately 42 arms. 
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3.2 Ex vivo binding of PEG/Succ-CD/SABpep and PEG/Succ-CD/SABpep/HABpep 
on conjunctival tissue 
The ex vivo rabbit eye study was done to examine the retention of HA of different 
eye drop solutions on ex vivo rabbit eyes over time, with each wash representing blinking 
of the eyes. The fluorescent value of each condition was measured after each wash with a 
total of 15 washes, and the eye drop was re-applied 2 more times, each with 15 washes. 
Each wash corresponds to 5 min, so these fluorescent values were then converted to 
concentration of HA-FL over time using a standard HA-FL curve, and then the percent of 
HA retained after each wash (or after every 5 min) was plotted against time. Figure 6 
shows the percent of HA retained over time comparing the control (which is the baseline 
with PBS + HA-FL), the SABpep-PEG/CD + HA-FL, the SABpep-PEG/CD-HABpep + 
HA-FL, and the 8-arm SABpep-PEG-HABpep + HA-FL. 
After the first wash (5 min), the SABpep-PEG/CD-HABpep retained 40% HA, 
the 8-arm SABpep-PEG-HABpep retained 33%, the SABpep-PEG/CD retained 29%, and 
the control (HA-FL only) retained 28%, with respect to the initial signal at time = 0 min, 
where the SABpep-PEG/CD-HABpep retained 51% HA, the 8-arm SABpep-PEG-
HABpep retained 42%, the SABpep-PEG/CD retained 40%, and the control (PBS + HA-
FL only) retained 43%. This demonstrates that after 5 min of eye drop application, 
SABpep-PEG/CD-HABpep retained ~1.2 times more HA than 8-arm SABpep-PEG-
HABpep, ~1.4 times more HA than SABpep-PEG/CD, and ~1.4 times more HA than the 
control. 
After 1 period of eye drop treatment (75 min or 1.25 h), the SABpep-PEG/CD-
HABpep retained 22% HA, the 8-arm SABpep-PEG-HABpep retained 18%, the 
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SABpep-PEG/CD retained 17%, and the control (PBS + HA-FL only) retained 15%. 
After the second period of eye drop treatment (195 min or 3.25 h), the SABpep-PEG/CD-
HABpep retained 20% HA, the 8-arm SABpep-PEG-HABpep retained 16%, the 
SABpep-PEG/CD retained 15%, and the control (PBS + HA-FL only) retained 13%. This 
second period followed the same trend as the first period where after each period, 
SABpep-PEG/CD-HABpep retained ~1.2 times more HA than 8-arm SABpep-PEG-
HABpep, ~1.3 times more HA than SABpep-PEG/CD, and ~1.5 times more HA than the 
control. 
After both the first and second periods of eye drop treatment (or 195 min) with 
about 75 min each period with 40 min in between for eye drop application, the SABpep-
PEG/CD-HABpep + HA-FL demonstrated the greatest retention of HA on the eye. This 
emphasizes that the HA binding eye drop technology with the PEG/Succinyl-CD polymer, 
SABpep, and HABpep has the greatest potential in increasing the retention time of HA 
on the ocular surface. This is due to the multivalency of the PEG/CD complex, which 
allows it to bind more HA, as compared to the control and other polymer-peptide systems. 
However, the third period of eye treatment (after 315 min or 5.25 h) shows a 
different trend where the SABpep-PEG/CD-HABpep retained 20% (which is the same as 
after the second period), but the 8-arm SABpep-PEG-HABpep retained 21%, the 
SABpep-PEG/CD retained 17%, and the control retained 20%. This could be due to the 
fact that the eye drops only have significant or accurate residence time before 200 min. 
After 200 min, there is no significant difference among groups and controls. 
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FIGURE 6. Ex vivo rabbit model study: Percent HA retained over time for the control (HA-FL only), 
PEG/CD bound only to SABpep with HA-FL, PEG/CD bound to both SABpep and HABpep with HA-FL, 
and 8-arm PEG bound to both SABpep and HABpep with HA-FL. 1st Graph-1st batch of application, 2nd 
graph-2nd batch of application, 3rd graph-3rd batch of application. 
 
3.3 In vivo binding of PEG/Succ-CD/SABpep/HABpep on mice 
The in vivo HA retention study had 4 different eye drop solutions that were 
compared at 3 different time points. The first eye drop solution was a negative control of 
PBS only (without HA-FL) (Figure 7A). The second eye drop solution was a negative 
control of SABpep-PEG/CD-HABpep only (Figure 7B). The third eye drop solution 
contained an equal volume mixture of PBS and 0.1% HA (as in commercial HA eye 
drops) (Figure 7C). The fourth eye drop solution contained an equal volume mixture of 
SABpep-PEG/CD-HABpep and 0.1% HA (Figure 7D). Each mouse eye that was imaged 
has a zoomed-in image below to show the details of the fluorescent intensity of the eye 
drop solution. Figures 7A and 7B show that the negative control eye drop solutions 
(without HA-FL) show no fluorescence in the mice eyes at 0 min, 15 min, or 30 min. 





















SABpep-PEG-HABpep (8-arm) + HA-FL
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This confirms our hypothesis since no HA-FL eye drop solution was added, so there 
should be no fluorescence in the mice eyes. The visible white spots that appear in these 
two figures are due to reflection of light from the eyes. Figures 7C and 7D depict that 
both the positive control and the sample eye drop solutions showed high, uniform 
fluorescence at 0 min. However, over time, the positive control eye drop solution was 
quickly vanishing and showed much less fluorescent intensity at 15 min, compared to the 
sample eye drop solution, and it showed no fluorescent intensity at 30 min, while the 
fluorescence of the sample eye drop solution was still present. To clarify it further, the 30 
min positive control eye (Figure 7C) shows no fluorescence; however, a fluorescent spot 
appears to be on the eyelid and not on the eye, and could be due to blinking of the eyes; 
thus, the positive control eye shows no fluorescence at 30 min. Also, at 15 min for 
Figures 7C and 7D for the positive control and sample eye drop solutions, respectively, 
they both exhibit fluorescence; however, the sample eye drop solution in Figure 7D 
shows a uniform layer of the solution on the eye, whereas the positive control solution in 
Figure 7C shows a thin fluorescent band of the solution at the bottom of the eye, 
possibly at the edge of the eye lid. Both eyes experienced blinking, but multivalent 
polymer-peptide, SABpep-PEG/CD-HABpep + HA-FL (sample) was able to retain the 
HA uniformly on the eye, whereas the positive control of PBS + HA-FL was not. This 
shows that the SABpep-PEG/CD-HABpep + HA-FL lasted well on the ocular surface at 
15 min and was still present at 30 min, whereas the control only lasted until 15 min but 
was not uniform and did not cover the surface of the eye. Initial and over time 
fluorescence of the positive control and sample eye drop solutions remained 
	 21	




A. Mice eyes 1L, 3L, and 5L with negative control eye drop solution of PBS only 
B. Mice eyes 1R, 3R, and 5R with negative control eye drop solution of SABpep-
PEG/CD-HABpep only 
1L (0min) Zoomed 
1L (0min) 3L (15 min) 
3L (15 min) Zoomed 
5L (30 min) 
5L (30 min) Zoomed 
1R (0min) Zoomed 
1R (0min) 3R (15 min) 
3L (15 min) Zoomed 
5R (30 min) 
5R (30 min) Zoomed 
���
C. Mice eyes 2L, 4L, and 6L with positive control eye drop solution of PBS + 0.1% HA-
FL 
D. Mice eyes 2L, 4L, and 6L with sample eye drop solution of SABpep-PEG/CD-
HABpep + 0.1% HA-FL 
2L (0min) Zoomed 
2L (0min) 4L (15 min) 
4L (15 min) Zoomed 
6L (30 min) 
6L (30 min) Zoomed 
2R (0min) Zoomed 
2R (0min) 4R (15 min) 
4R (15 min) Zoomed 
6R (30 min) 
6R (30 min) Zoomed 
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FIGURE 7. Fluorescent images of in vivo eye drop treatment in mice eyes. The figure is divided up into 4 
sets, where each set shows zoomed-in images of each eye. A compares the negative control mice eyes 1L 
(mouse 1, left eye), 3L, and 5L where only PBS was applied at different time points t = 0 min, 15 min, and 
30 min, respectively. B compares the negative control mice eyes 1R, 3R, and 5R where only the 
multivalent polymer-peptide was applied (SABpep-PEG/CD-HABpep) at different time points t = 0 min, 
15 min, and 30 min, respectively. C compares the positive control mice eyes 2L, 4L, and 6L where PBS 
and HA-FL were applied at different time points t = 0 min, 15 min, and 30 min, respectively. D compares 
the sample mice eyes 2R, 4R, and 6R where SABpep-PEG/CD-HABpep and HA-FL were applied at 
different time points t = 0 min, 15 min, and 30 min, respectively. 
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4. DISCUSSION 
Eye drops have become a conventional form for ocular therapy, and they now 
represents 90% of the market for ocular conditions due to their simplicity of development 
and production.23 It has been shown through studies mentioned previously that 
incorporating hyaluronic acid in these eye drops helps improve ocular residence time of 
these eye drops. Thus, there are several eye drop products in the market7, shown in 
Figure 8. The commercially available eye drops containing 0.1-0.2% hyaluronic acid 
(HA) solutions, such as OpticalmTM, ScopeTM, and OxyalTM are commonly used as an 
active ingredient in Europe to relieve dry eye symptoms, while in USA as an inactive 
ingredient of the eye drop formulation (e.g. in BlinkTM). Figure 8 shows 10 different 
types of eye drops and their status of FDA approval. The only eye drop product that is 
FDA approved and sold in the US market is BlinkTM, where its main component is 0.25% 
PEG and HA is listed as an inactive ingredient. One of the disadvantages of these 
products is that they show low ocular residence time since these current eye drops reside 
in the aqueous layer of the tear film on the ocular surface, so after some blinking, the eye 
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FIGURE 8. HA and modified-HA artificial tear products. 
 
The novel idea of the polymer-peptide system is that it immobilizes the HA onto 
the mucin layer of the ocular surface, allowing for enhanced binding as opposed to 
having HA in the aqueous layer of the tear film. Theoretically, since HA is immobilized 
onto the ocular surface with this system, it should be able to reside on the ocular surface 
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for a longer amount of time since the bond is supposedly stronger so the blinking should 
not affect the eye drop as much, especially in the earlier time points. 
In previous studies done by Lee el al.25, they found that immobilizing HA using 
an HABpep by developing a heterobifunctional polymer-peptide system with SABpep at 
the other end of the spacer PEG molecule showed that HA was bound 1.8 times more in 
the beginning and ~1.2 times more at 24 h through 2-arm SABpep-PEG-HABpep 
compared to control (HA only), through their ex vivo rabbit experiment. They also found 
that through their in vivo mouse model, the heterobifunctional polymer-peptide system 
(2-arm PEG) was observed even at 15 min compared to 5 min for the control HA that 
was not bound with the peptide. 
In comparison, this novel PEG/Succ-CD complex with multivalent binding of 
SABpep and HABpep to SA and HA, respectively, in the ex vivo rabbit model 
demonstrated that it initially retained ~1.2 times more HA than 8-arm SABpep-PEG-
HABpep, ~1.4 times more HA than SABpep-PEG/CD, and ~1.4 times more HA than the 
control. And after period 1 and 2 of eye drop application, or 75 min or 195 min, the novel 
SABpep-PEG/CD-HABpep retained ~1.2 times more HA than 8-arm SABpep-PEG-
HABpep, ~1.3 times more HA than SABpep-PEG/CD, and ~1.5 times more HA than the 
control. This shows that this multivalent polymer-peptide system has higher binding of 
HA to the ocular surface than the 8-arm polymer-peptide system, as well as the control 
(without the peptide). These results, however, cannot show higher binding of HA to the 
ocular surface than the heterobifunctional polymer-peptide system (2-arm) that was 
produced in the study done by Lee et al25, since the experimental setup and methods were 
different. But theoretically, this multivalent polymer-peptide system should show higher 
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retention of HA to the ocular surface than the 2-arm polymer-peptide system, since the 
number of arms/valency is higher. 
In the in vivo mouse model, the novel eye drop technology of a multivalent 
polymer-peptide system (SABpep-PEG/CD-HABpep + HA-FL) showed that this eye 
drop solution lasted up to 30 min, while the positive control containing PBS + HA-FL 
only lasted up to 15 min. Both these eye drop solutions showed high initial fluorescence 
at time t = 0 min; however, the control was quickly vanishing and even after 15 min, it 
was almost depleted, but after 30 min, only the SABpep-PEG/CD-HABpep + HA-FL eye 
drop was retained on the mouse eye. Thus, the preliminary results from this model 
emphasized that the multivalent polymer-peptide eye drop had a residence time of ≤ 30 
minutes, as compared to ≤ 15 minutes for the heterobifunctional polymer-peptide eye 
drops (2-arm PEG) and for the commercially-available HA-based eye drops. This shows 
that the novel eye drop technology does have great potential to be an effective treatment 




In summary, we developed a new eye drop technology using a multivalent 
polymer-peptide system that immobilizes HA onto the ocular surface using sialic acid as 
an anchor. The retention time of this eye drop technology was significantly improved 
compared to previous technologies, as it retained ~1.5 times more HA than 
commercially-available eye drops through ex vivo rabbit eye studies and had a residence 
time of ≤ 30 minutes through in vivo mice eye studies, as compared to ≤ 15 minutes for 
previous eye drop technologies. Even though other pre-clinical tests are needed, we 
anticipate that this HA eye drop would reduce the frequency of eye-drop instillation and 
also more effectively alleviate dry eye symptoms by improving water retention. 
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6. FUTURE DIRECTIONS 
The in vivo mouse model done in this study showed preliminary results that imply 
the great potential of this multivalent polymer-peptide system to increase HA retention 
time on the ocular surface. However, this in vivo test should be repeated to confirm these 
results and to compare this eye drop technology to the 8-arm SABpep-PEG-HABpep and 
the 2-arm SABpep-PEG-HABpep technologies, to investigate if this eye drop can retain 
HA for 30 minutes, which should be longer than the other eye drops. 
We are currently performing isothermal titration calorimetry (ITC) protocol to 
explore the binding affinity of HA to 2-arm x-PEG-HABpep, 8-arm PEG-HABpep, and 
multivalent PEG/Succ-CD/HABpep, as well as the binding affinity of mucin (or sialic 
acid) to 2-arm PEG-SABpep, 8-arm PEG-SABpep, and multivalent PEG/Succ-
CD/SABpep. We hypothesize that the binding affinity of the multivalent PEG/CD 
complex would have a higher binding affinity to both HA and mucin than the 8-arm PEG, 
which would have a higher binding affinity than the 2-arm PEG. This is because more 
arms/branching/valency should indicate a higher binding affinity. Once this hypothesis is 
confirmed, then we can run ITC to explore the binding affinity of HA and mucin to the 
full polymer-peptides systems: 2-arm SABpep-PEG-HABpep, 8-arm SABpep-PEG-
HABpep, and SABpep-PEG/Succ-CD-HABpep. As mentioned previously, we 
hypothesize that SABpep-PEG/Succ-CD-HABpep would have a higher binding affinity 
to both HA and mucin than the 8-arm SABpep-PEG-HABpep, which would have a 
higher binding affinity than the 2-arm SABpep-PEG-HABpep, due to increasing number 
of arms/valency. 
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In a future test, we would like to run ocular biomechanical friction test with our 
collaborator (Prof. Tannin A. Schmidt’s laboratory) at the University of Connecticut. We  
hypothesize that rabbit ocular tissues treated with our multivalent polymer-peptide 
system (SABpep-PEG/CD-HABpep) and HA solution would have reduced kinetic 
coefficient of friction values, and therefore improved tissue lubrication, compared to HA-
only treated tissues as control and the 2 other heterofunctional eye drops (2-arm SABpep-
PEG-HABpep and 8-arm SABpep-PEG-HABpep). 
A future direction for this project could be implementing dendrimers to allow 
even more HABpep and SABpep to bind, potentially increasing HA retention time even 
more, or, enhance the multi-valency in the present system. Dendrimers are star-shaped 
macromolecules that are highly branched, where they also display multivalency. This 
could be another method to improve HA retention on the ocular surface as an effective 
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